Vero Biotech: Funding, Investors & Team (Sep 2026)
Vero Biotech is a biopharmaceutical company focused on the design, development, and commercialization of next-generation products to address the unmet medical needs of patients with a variety of pulmonary and cardiac diseases. We are currently developing inhaled nitric oxide (NO) products for use in both the hospital setting and for longer-term applications outside of the hospital setting. These products, which are based on our GeNOsyl™ drug delivery technology, are comprised of a single-use drug cassette and either a portable console or wearable controller. Our technology is designed to deliver NO safely for a variety of therapeutic indications and to provide clinicians with a solution that is more user-friendly than currently available NO delivery systems.
Vero Biotech has raised $100M across 1 funding round on record, the most recent a Series E of $100M announced in Dec 2021.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Vero Biotech Company Profile and Key Stats
Latest funding round on record: Dec 2021.
Vero Biotech Funding Rounds
Vero Biotech Founders and Leadership Team
No contact details are on record for this team yet.
Vero Biotech Funding Compared to Other Biotechnology Startups
Vero Biotech's latest round of $100M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Vero Biotech in Biotechnology and Atlanta
Companies Similar to Vero Biotech
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…
Solstice Oncology is a clinical stage immuno-oncology company
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…
BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Vero Biotech Funding FAQs
What does Vero Biotech do?
Vero Biotech is a biopharmaceutical company focused on the design, development, and commercialization of next-generation products to address the unmet medical needs of patients with a variety of pulmonary and cardiac diseases. We are currently developing inhaled nitric oxide (NO) products for use in both the hospital setting and for longer-term applications outside of the hospital setting. These products, which are based on our GeNOsyl™ drug delivery technology, are comprised of a single-use drug cassette and either a portable console or wearable controller. Our technology is designed to deliver NO safely for a variety of therapeutic indications and to provide clinicians with a solution that is more user-friendly than currently available NO delivery systems.
How much funding has Vero Biotech raised?
Vero Biotech has raised $100M across 1 round on record. The most recent is a Series E of $100M announced in Dec 2021.
When did Vero Biotech last raise funding?
Vero Biotech's most recent funding round on record is a Series E of $100M, announced in Dec 2021.
Who is the CEO of Vero Biotech?
Kurt Dasse is listed as CEO at Vero Biotech.
Where is Vero Biotech headquartered?
Vero Biotech is based in Atlanta, Georgia, United States.
How many employees does Vero Biotech have?
Vero Biotech is in the 101-250 employee band.
How does Vero Biotech's funding compare to other Biotechnology startups?
Vero Biotech's latest round of $100M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Vero Biotech Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Vero Biotech is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.